Label-free quantitative proteomics reveals fibrinopeptide B and heparin cofactor II as potential serum biomarkers in respiratory syncytial virus-infected mice treated with Qingfei oral liquid formula.
10.1016/S1875-5364(18)30054-2
- Author:
Li-Hua ZHOU
1
,
2
;
Jian-Ya XU
3
;
Chen DAI
4
;
Yi-Man FAN
3
;
Bin YUAN
5
Author Information
1. Jiangsu Key Laboratory of Pediatric Respiratory Disease, Nanjing University of Chinese Medicine, Nanjing 210023, China
2. College of Medicine and Life Sciences, Nanjing University of Chinese Medicine, Nanjing 210023, China.
3. Jiangsu Key Laboratory of Pediatric Respiratory Disease, Nanjing University of Chinese Medicine, Nanjing 210023, China.
4. Experimental Teaching Center of Life Science, Nanjing Agricultural University, Nanjing 210095, China.
5. Department of Pediatrics, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China. Electronic address: yuanbin68358@163.com.
- Publication Type:Journal Article
- Keywords:
Label-free quantitative proteomics;
Potential serum biomarkers;
Qingfei oral liquid;
RSV-host interaction network;
Respiratory syncytial virus-infected mouse pneumonia model
- MeSH:
Animals;
Biomarkers;
blood;
Chromatography, Liquid;
Disease Models, Animal;
Drugs, Chinese Herbal;
pharmacology;
therapeutic use;
Fibrinopeptide B;
analysis;
genetics;
Gene Expression Regulation;
drug effects;
Heparin Cofactor II;
analysis;
genetics;
Lung;
pathology;
Mice, Inbred BALB C;
Proteome;
drug effects;
Proteomics;
Respiratory Syncytial Virus Infections;
blood;
drug therapy;
Respiratory Syncytial Viruses;
drug effects;
Tandem Mass Spectrometry
- From:
Chinese Journal of Natural Medicines (English Ed.)
2018;16(4):241-251
- CountryChina
- Language:English
-
Abstract:
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections. Qingfei oral liquid (QFOL), a traditional Chinese medicine, is widely used in clinical treatment for RSV-induced pneumonia. The present study was designed to reveal the potential targets and mechanism of action for QFOL by exploring its influence on the host cellular network following RSV infection. We investigated the serum proteomic changes and potential biomarkers in an RSV-infected mouse pneumonia model treated with QFOL. Eighteen BALB/c mice were randomly divided into three groups: RSV pneumonia model group (M), QFOL-treated group (Q) and the control group (C). Serum proteomes were analyzed and compared using a label-free quantitative LC-MS/MS approach. A total of 172 protein groups, 1009 proteins, and 1073 unique peptides were successfully identified. 51 differentially expressed proteins (DEPs) were identified (15 DEPs when M/C and 43 DEPs when Q/M; 7 DEPs in common). Classification and interaction network showed that these proteins participated in various biological processes including immune response, blood coagulation, complement activation, and so forth. Particularly, fibrinopeptide B (FpB) and heparin cofactor II (HCII) were evaluated as important nodes in the interaction network, which was closely involved in coagulation and inflammation. Further, the FpB level was increased in Group M but decreased in Group Q, while the HCII level exhibited the opposite trend. These findings not only indicated FpB and HCII as potential biomarkers and targets of QFOL in the treatment of RSV pneumonia, but also suggested a regulatory role of QFOL in the RSV-induced disturbance of coagulation and inflammation-coagulation interactions.
